Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Rating of “Buy” from Brokerages

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has been assigned a consensus rating of “Buy” from the seven research firms that are currently covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $65.00.

A number of brokerages have recently weighed in on ARCT. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, December 16th. BTIG Research initiated coverage on Arcturus Therapeutics in a research note on Tuesday, January 28th. They set a “buy” rating and a $41.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $63.00 price target on shares of Arcturus Therapeutics in a research report on Monday, January 13th.

Arcturus Therapeutics Stock Down 1.3 %

Shares of NASDAQ ARCT opened at $15.86 on Thursday. The stock has a market cap of $429.65 million, a P/E ratio of -7.14 and a beta of 2.62. The firm’s 50-day simple moving average is $17.09 and its 200 day simple moving average is $19.06. Arcturus Therapeutics has a fifty-two week low of $14.30 and a fifty-two week high of $45.00.

Institutional Investors Weigh In On Arcturus Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. nVerses Capital LLC acquired a new stake in shares of Arcturus Therapeutics during the third quarter worth $42,000. KLP Kapitalforvaltning AS purchased a new position in Arcturus Therapeutics in the 4th quarter worth about $71,000. China Universal Asset Management Co. Ltd. raised its holdings in Arcturus Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock worth $121,000 after buying an additional 2,038 shares during the period. National Bank of Canada FI lifted its stake in Arcturus Therapeutics by 639.6% during the fourth quarter. National Bank of Canada FI now owns 5,532 shares of the biotechnology company’s stock valued at $94,000 after buying an additional 4,784 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of Arcturus Therapeutics in the third quarter worth about $191,000. Institutional investors and hedge funds own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.